Dan Hicklin

Dr. Dan Hicklin is an accomplished cancer researcher and biopharmaceutical executive with over three decades of oncology drug development experience.

Prior to his current positions, he founded Potenza Therapeutics (acquired by Astellas Pharma) where he was President and CEO, served as President and CSO of CoStim Pharmaceuticals (acquired by Novartis), and was on the board of directors of Harpoon Therapeutics and the scientific advisory board of Oncorus.

Earlier in his career, Dr. Hicklin held several positions at Merck Research Laboratories (formerly the Schering-Plough Research Institute), including leading their Biologics Strategy for Oncology and the Immuno-Modulation Discovery team. In these roles, he oversaw several oncology discovery and development projects including Merck’s immuno-oncology portfolio and the development of Keytruda® (pembrolizumab).

Before joining Schering-Plough, Dr. Hicklin held several positions of increasing responsibility at ImClone Systems (acquired by Eli Lilly), including Vice President of Experimental Therapeutics. His team at ImClone supported the development and FDA approval of the cancer treatment Erbitux® (cetuximab) and built a diversified portfolio of antibody therapeutics including Cyramza® (ramucirumab), Portrazza® (necitumumab), Lartruvo® (olaratumab), and other agents that were acquired by Eli Lilly.

Dr. Hicklin holds an M.S. and Ph.D. in Immunology from New York Medical College where he trained with Dr. Soldano Ferrone, and a B.S. from the University of Iowa.